N-(tert-Butoxycarbonyl)-D-threonine Methyl Ester>98.0%(HPLC)(N)5g

1-((9H-fluoren-9-yl)methyl)piperidine, 95.0%, 100mg

Hydroxyvalerenic acid, with analyt. Documents, 100 mg, glass packaging

Methyl 4-bromo-2,5-difluorobenzoate, 95.0%, 25g

(3R,6S)-5-[(tert-butoxy)carbonyl]-1,1-difluoro-5-azaspiro[2.4]heptane-6-carboxylic acid, 97%, 100mg

E-Plan phase EPLPHi 10x/0.25 infinity corrected IOS objective. Working distance 5.95 mm

(R)-(+)-2-Amino-3-methyl-1,1-diphenyl-1-butanol, 95.0%, 25g

4-Octylbenzoic acid, 95.0%, 25g

3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, 95.0%, 5g

trans-1,3-Diphenyl-2-propen-1-ol>97.0%(GC)5g

5-(benzo[d]thiazol-2-yl)thiophene-2-carbonyl chloride, 95.0%, 250mg

(E)-METHYL 3-(3,4-DIFLUOROPHENYL)ACRYLATE, 95.0%, 5g

2-Phenylethanethiol, 95.0%, 10g